Raj Singh1,2,3,4,5,6, Hayden Ansinelli2, Dana Sharma3, Jan Jenkins4, Joanne Davis4, Sanjeev Sharma3,5, John Austin Vargo6. 1. Department of Radiation Oncology, Virginia Commonwealth University Health System, Richmond, VA 23298, USA. 2. Department of Radiation Oncology, University of Arizona, Tucson, AZ 85719, USA. 3. Department of Radiation Oncology, Marshall University Joan C. Edwards School of Medicine, Huntington, WV 25701, USA. 4. The Radiosurgery Society, Sunnyvale, CA 94402, USA. 5. Department of Radiation Oncology, St. Mary's Medical Center, Huntington, WV 25701, USA. 6. Department of Radiation Oncology, University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA 15232, USA.
Abstract
Objectives: Examine local control(LC), overall survival(OS), and toxicity following stereotactic body radiation therapy(SBRT) for patients with metastatic renal cell carcinoma(mRCC). Methods: A multi-institutional registry was queried. Potential predictive factors of LC and OS were evaluated with a Cox-proportional hazards model for multivariate analysis(MVA). Results: We identified 115 mRCC patients with 181 lesions. Median biologically effective dose (BED7) was 72.9 Gy7 (range: 42.9-231.4 Gy7) with a median dose/fraction of 10 Gy (range: 5-24 Gy). Utilizing both Karnofsky Performance Score (KPS) and presence of osseous metastatic disease as prognostic indicators, estimated 2-year OS rates were 67.7% (95% CI: 49.9-89.5%), 31.8% (95% CI: 19.0-45.3%), and 20% (95% CI: 1.4-54.7%; p=0.0012). One- and 2-year LC rates were 88.2% and 82.7%, respectively, with no prognostic factors identified. Roughly 13% of patients reported toxicities with one Grade 3-5 toxicity. Conclusion: SBRT was well-tolerated with promising LC. Both KPS and osseous metastatic disease should be considered in determining which patients with mRCC may preferentially benefit from SBRT.
Objectives: Examine local control(LC), overall survival(OS), and toxicity following stereotactic body radiation therapy(SBRT) for patients with metastatic renal cell carcinoma(mRCC). Methods: A multi-institutional registry was queried. Potential predictive factors of LC and OS were evaluated with a Cox-proportional hazards model for multivariate analysis(MVA). Results: We identified 115 mRCC patients with 181 lesions. Median biologically effective dose (BED7) was 72.9 Gy7 (range: 42.9-231.4 Gy7) with a median dose/fraction of 10 Gy (range: 5-24 Gy). Utilizing both Karnofsky Performance Score (KPS) and presence of osseous metastatic disease as prognostic indicators, estimated 2-year OS rates were 67.7% (95% CI: 49.9-89.5%), 31.8% (95% CI: 19.0-45.3%), and 20% (95% CI: 1.4-54.7%; p=0.0012). One- and 2-year LC rates were 88.2% and 82.7%, respectively, with no prognostic factors identified. Roughly 13% of patients reported toxicities with one Grade 3-5 toxicity. Conclusion: SBRT was well-tolerated with promising LC. Both KPS and osseous metastatic disease should be considered in determining which patients with mRCC may preferentially benefit from SBRT.
Authors: Rana R McKay; Xun Lin; Julia J Perkins; Daniel Y C Heng; Ronit Simantov; Toni K Choueiri Journal: Eur Urol Date: 2014-02-26 Impact factor: 20.096
Authors: Arya Amini; Basel Altoos; Maria T Bourlon; Edward Bedrick; Shilpa Bhatia; Elizabeth R Kessler; Thomas W Flaig; Christine M Fisher; Brian D Kavanagh; Elaine T Lam; Sana D Karam Journal: Pract Radiat Oncol Date: 2015-06-30
Authors: M Bianchi; M Sun; C Jeldres; S F Shariat; Q-D Trinh; A Briganti; Z Tian; J Schmitges; M Graefen; P Perrotte; M Menon; F Montorsi; P I Karakiewicz Journal: Ann Oncol Date: 2011-09-02 Impact factor: 32.976
Authors: Yuanyuan Zhang; Jonathan Schoenhals; Alana Christie; Osama Mohamad; Chiachien Wang; Isaac Bowman; Nirmish Singla; Hans Hammers; Kevin Courtney; Aditya Bagrodia; Vitaly Margulis; Neil Desai; Aurelie Garant; Hak Choy; Robert Timmerman; James Brugarolas; Raquibul Hannan Journal: Int J Radiat Oncol Biol Phys Date: 2019-08-01 Impact factor: 7.038
Authors: Amol J Ghia; Eric L Chang; Andrew J Bishop; Hubert Y Pan; Nicholas S Boehling; Behrang Amini; Pamela K Allen; Jing Li; Laurence D Rhines; Nizar M Tannir; Claudio E Tatsui; Paul D Brown; James N Yang Journal: J Neurosurg Spine Date: 2016-01-22
Authors: Basel Altoos; Arya Amini; Muthanna Yacoub; Maria T Bourlon; Elizabeth E Kessler; Thomas W Flaig; Christine M Fisher; Brian D Kavanagh; Elaine T Lam; Sana D Karam Journal: Radiat Oncol Date: 2015-10-28 Impact factor: 3.481